BioDelivery Sciences Soars on Positive Trial Data (BDSI)

BioDelivery Sciences BDSI Shares of BioDelivery Sciences International (BDSI) soared 22% in active premarket trade after the company and its partner, Endo Pharmaceuticals, said a late-stage trial of its severe pain treatment met its primary efficacy endpoint.

At 10:30 AM the stock is up 15.51 % form Fridays close to $13.87 and touched a new high briefly at $14.38. Volume is high with 3.5 million shared trading hands. Normal volume is 726K shares per day.

BioDelivery Sciences International, Inc., (BDSI)  a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care.

BioDelivery (BDSI) showed that its drug called Bema buprenorphine, which being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, successfully met its primary efficacy endpoint in demonstrating that the drug resulted in “significantly improved chronic pain relief compared to placebo,” according to the trial results.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.


One thought on “BioDelivery Sciences Soars on Positive Trial Data (BDSI)

Leave a Reply

Your email address will not be published. Required fields are marked *